

Bipolar Disorder Therapeutic and Drug Pipeline Review H2

Bipolar Disorder Treatment Pipeline Review H2 2016

PUNE, INDIA, November 21, 2016

/EINPresswire.com/ -- Get Sample

Report @

<https://www.wiseguyreports.com/sample-request/752826-bipolar-disorder-manic-depression-pipeline-review-h2-2016>

Bipolar disorder was formerly called manic depression. It is a form of major affective disorder, or mood disorder, defined by manic or hypomanic episodes. Symptoms include decreased appetite and/or weight loss, or overeating and weight gain, fatigue, decreased energy, being slowed down, insomnia, early-morning awakening, or oversleeping, restlessness and irritability. The predisposing factors include age, stress and family history. Treatment includes anticonvulsants, antipsychotics and antidepressants.



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Bipolar Disorder (Manic Depression) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Bipolar Disorder (Manic Depression) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 10, 6 and 4 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively. Bipolar Disorder (Manic Depression).

Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time

basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bipolar Disorder (Manic Depression) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Bipolar Disorder (Manic Depression) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bipolar Disorder (Manic Depression) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bipolar Disorder (Manic Depression) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bipolar Disorder (Manic Depression) (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bipolar Disorder (Manic Depression) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Bipolar Disorder (Manic Depression) Overview 10

Therapeutics Development 11

Pipeline Products for Bipolar Disorder (Manic Depression) - Overview 11

Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis 12

Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies 13

Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes 15

Bipolar Disorder (Manic Depression) - Pipeline Products Glance 16

Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Bipolar Disorder (Manic Depression) - Products under Development by Companies 19
Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes 21
Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development 22
Aequus Pharmaceuticals Inc. 22
Amorsa Therapeutics Inc. 23
AstraZeneca Plc 24
Biogen Inc 25
Delpor, Inc. 26
Intas Pharmaceuticals Ltd. 27
...Continued

Access Report @ <https://www.wiseguyreports.com/reports/752826-bipolar-disorder-manic-depression-pipeline-review-h2-2016>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.